Revolution Medicines, Inc. RVMD Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Revolution Medicines, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Revolution Medicines, Inc.'s cash & equivalents?
- Revolution Medicines, Inc. (RVMD) reported cash & equivalents of $440.94M in Q1 2026.
- How has Revolution Medicines, Inc.'s cash & equivalents changed year-over-year?
- Revolution Medicines, Inc.'s cash & equivalents increased by 32.2% year-over-year, from $333.55M to $440.94M.
- What is the long-term trend for Revolution Medicines, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Revolution Medicines, Inc.'s cash & equivalents has grown at a 29.8% compound annual growth rate (CAGR), from $104.27M to $383.75M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.